Kiniksa Pharmaceuticals Ltd (KNSA)
16.91
+0.03
(+0.18%)
USD |
NASDAQ |
Apr 19, 16:00
16.89
-0.02
(-0.12%)
After-Hours: 20:00
Kiniksa Pharmaceuticals Revenue (TTM): 270.26M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 270.26M |
| September 30, 2023 | 248.75M |
| June 30, 2023 | 280.84M |
| March 31, 2023 | 236.34M |
| Date | Value |
|---|---|
| December 31, 2022 | 220.18M |
| September 30, 2022 | 177.04M |
| June 30, 2022 | 90.00M |
| March 31, 2022 | 70.73M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
70.73M
Minimum
Mar 2022
280.84M
Maximum
Jun 2023
199.27M
Average
228.26M
Median
Revenue (TTM) Benchmarks
| Amicus Therapeutics Inc | 399.36M |
| Geron Corp | 0.237M |
| United Therapeutics Corp | 2.328B |
| Vanda Pharmaceuticals Inc | 192.64M |
| TG Therapeutics Inc | 233.66M |